Meenakshi, M (2016) A comparative study on the efficacy of methotrexate Vs dapsone Vs ASST (Autologous Serum Skin Therapy) for treatment of chronic urticaria. Masters thesis, Madras Medical College, Chennai.
|
Text
2020001meenakshim.pdf Download (5MB) | Preview |
Abstract
Chronic urticaria (CU) is a common skin disorder affecting 15–20% people in the general population.Pathogenesis of CU is unclear and possible causes may include chronic infections, allergy to certain food or food additives, anxiety, and autoantibody production against IgE receptor. It remains a major problem in terms of etiology, investigation, and management and causes comorbidity and high cost to the health care system. 1. Proper evaluation is mandatory to find out the presence of precipitating factor and if present, management of the same 2. ASST can be considered as a first line of treatment, in patients with chronic urticaria, especially in those who are positive for Autologous Serum Skin Test. The preferred regimen being 2ml of autologous serum given as deep intramuscular injections once a week for nine weeks 3. Dapsone can be considered for patients refractory to treatment. The regimen being 50mg daily for a period of 12 weeks. 4. Methotrexate is recommended as last resort, in patients who are refractory to other modalities of treatment. Side effects profile and its contraindication in patients with haematological problems, restrict its more common usage 5. A randomized, controlled study with prolonged follow up and involving much more modalities of treatment is necessary to devise an accepted management protocol for patients with chronic urticaria.
| Item Type: | Thesis (Masters) |
|---|---|
| Uncontrolled Keywords: | Methotrexate ; Vapsone ; autologous serum skin therapy ; Chronic Urticaria. |
| Subjects: | MEDICAL > Dermatology Venereology and Leprosy |
| Depositing User: | Punitha K |
| Date Deposited: | 26 Jul 2017 12:07 |
| Last Modified: | 01 Mar 2018 02:20 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/2200 |
Actions (login required)
 |
View Item |
